ceapro inc
(CZO:Canadian Ventures Exchange)

Last C$0.06 CAD

Change Today 0.00 / 0.00%

Volume 10.0K

CZO On Other Exchanges

Symbol

Exchange

CZO:CN

CRPOF:US

OTC US

As of 12:35 PM 05/17/13 All times are local (Market data is delayed by at least 15 minutes).

ceapro inc (CZO) Snapshot

Open C$0.06		Previous Close C$0.06
Day High C$0.06		Day Low C$0.06
52 Week High 05/22/12 - C$0.13		52 Week Low 12/4/12 - C$0.04
Market Cap 3.6M		Average Volume 10 Days 21.2K
EPS TTM C$-0.0040		Shares Outstanding 60.3M
EX-Date --		P/E TM --
Dividend --		Dividend Yield --

Current Stock Chart for CEAPRO INC (CZO)

CZO:CN Historical Stock Quote
CZO:CN Advanced Stock Chart

Related News

No related news articles were found.

ceapro inc (CZO) Related Businessweek News

No Related Businessweek News Found

ceapro inc (CZO) Details

Ceapro Inc., a biotechnology company, engages in the development and commercialization of health and wellness products primarily in the United States and Canada. It markets natural active ingredients, including beta glucan, avenanthramides, oat powder, oat oil, oat peptides, and lupin peptides to personal care, cosmetic, medical, and animal health industries through its distribution partners and direct sales; and veterinary therapeutic products comprising an oat shampoo, an ear cleanser, and a dermal complex/conditioner for veterinarians in Japan and Asia. The company’s products and technologies under research and development, or pre-commercial stage include CeaProve, a diabetes test meal to screen pre-diabetes and to determine dosage levels for diabetes oral therapy, and to monitor the condition of pre-diabetics; a drug delivery platform using its beta glucan technology to deliver compounds for uses ranging from wound care and therapy to skin care treatments that reduce the signs of aging; active ingredients product; and various novel manufacturing technologies. Ceapro Inc. is headquartered in Edmonton, Canada.

Detailed CZO:CN Company Description...

www.ceapro.com

ceapro inc (CZO) Top Compensated Officers

Mr. Gilles R. Gagnon M.Sc., MBA

Chief Executive Officer, President and Direct...

Age: 58

Total Annual Compensation: C$190.0K

Mr. Branko Jankovic CA

Chief Financial Officer, Vice President and C...

Total Annual Compensation: C$124.2K

Mr. David Fielder M.Sc.

Chief Scientific Officer

Total Annual Compensation: C$136.2K

Executives, Board Directors

Compensation as of Fiscal Year 2011.

ceapro inc (CZO) Key Developments

Ceapro Inc. Reports Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2013

May 15 13

Ceapro Inc. reported unaudited consolidated financial results for the first quarter ended March 31, 2013. For the quarter, the company reported revenue of $2,012,279 compared to revenue $1,189,513 for the same period a year ago. Income from operations of $402,811 compared to income from operations of $16,297 last year. Net income was $408,171 or $0.01 per basic and diluted share compared to net loss of $3,516 or $0.00 per basic and diluted share last year.

Ceapro Inc. Signs License and Distribution Agreement with Symrise AG

May 9 13

Ceapro Inc. announced the signing of an agreement with Symrise AG to specific key major players in the cosmetic market. Furthermore, Symrise will provide Ceapro with financial support under the form of a significant line of credit until April 1, 2016.

Ceapro Inc. Auditor Raises 'Going Concern' Doubt

Apr 19 13

Ceapro Inc. filed its Annual on Apr 19, 2013 for the period ending Dec 31, 2012. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.